Doing or planning to do business outside of the US? Visit our sister companies. RQMIS AR LTD. or RQMIS EU SL More


MassBio Forum: Clinical Evidence in the EU and CER Requirements


RQMIS President and Founder Barry Sands will be moderating a panel of prestigious industry experts at this exciting forum on October 24th. Titled "Tackling New EU Requirements for Clinical Evidence for Combination Products (Including Auto-injectors and Topicals)". This forum will focus on the new EU Medical Device Regulations requirements for medical devices, including combination products effective June 2020, and will provide insight from industry representatives on how they are addressing these significant new requirements. Click to learn more.

Q1 Productions - EU Medical Device Post-Market Clinical Evaluation Planning conference


President and Founder, Barry E. Sands, has been invited to speak at the EU Medical Device Post-Market Clinical Evaluation Planning conference hosted by Q1 Productions from October 20-29 in Frankfurt, Germany.

As described by Q1 Productions, the conference "will provide insight into practical solutions implemented by medical device firms to determine the appropriate level of evidence needed, and to develop plans to meet enhanced post-market clinical follow-up requirements." Click to learn more

MEDICA 2019 Conference - World Forum for Medicine


RQMIS is excited to be participating in MEDICA 2019 - the world's leading international medical trade fair. The conference will be held in Dusseldorf, Germany and will showcase over 5,000 exhibitors from 70 countries.

This year RQMIS has been invited to the Corporate Executive Office in the US Pavilion, organized and supported by the U.S. Department of Commerce. Our goal is to meet with existing and prospective clients to give them more insight into our unique approach for bringing their products to market. Come visit us in Hall 16! Click to learn more

Ready to get started?

We’ll drop you a line and start a conversation. Just put in your email. We won’t spam you.